<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127514</url>
  </required_header>
  <id_info>
    <org_study_id>AMX-3500</org_study_id>
    <nct_id>NCT03127514</nct_id>
  </id_info>
  <brief_title>AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>CENTAUR</acronym>
  <official_title>Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amylyx Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALS Finding a Cure Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northeast ALS Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital Neurology Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leandro P. Rizzuto Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amylyx Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CENTAUR trial will be a 2:1 (active:placebo) randomized, double-blind, placebo-controlled
      Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key
      cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This
      clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow
      decline in function as measured by the ALSFRS-R. The trial will also assess the effects of
      AMX0035 on muscle strength, vital capacity, and biomarkers of ALS including markers of
      neuronal death and neuroinflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Actual">November 24, 2019</completion_date>
  <primary_completion_date type="Actual">September 25, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALSFRS-R Slope</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in slope of ALS Functional Rating Scale over treatment duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Comparison Between Groups of Incidence of Adverse Events Until Planned Completion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects in each group able to remain on study drug until planned discontinuation</measure>
    <time_frame>24 weeks</time_frame>
    <description>A comparison of the proportion of subjects in each group able to remain on study drug until planned discontinuation between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accurate Testing of Limb Isometric Strength (ATLIS)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in rate of decline of isometric muscle strength over treatment duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood-based Biomarkers</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in levels of plasma-based biomarkers of neuronal death and axonal integrity from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Vital Capacity</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in slope of slow vital capacity decline over treatment duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival, tracheostomy and hospitalizations</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Comparison of rate of occurrence between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Biomarkers</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Motor Neuron Disease</condition>
  <condition>Neuromuscular Diseases</condition>
  <condition>Neurodegenerative Diseases</condition>
  <condition>Spinal Cord Diseases</condition>
  <condition>TDP-43 Proteinopathies</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered twice daily p.o. for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMX0035</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMX0035 administered twice daily p.o. for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMX0035</intervention_name>
    <description>AMX0035</description>
    <arm_group_label>AMX0035</arm_group_label>
    <other_name>Tauroursodeoxycholic Acid and Sodium Phenylbutyrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female, aged 18-80 years of age

          2. Sporadic or familial ALS diagnosed as definite as defined by the World Federation of
             Neurology revised El Escorial criteria

          3. Less than or equal to 18 months since ALS symptom onset

          4. Capable of providing informed consent and following trial procedures

          5. Slow Vital Capacity (SVC) &gt;60% of predicted value for gender, height, and age at the
             Screening Visit

          6. Subjects must either not take riluzole or be on a stable dose of riluzole for at least
             30 days prior to the Screening Visit. Riluzole-naïve subjects are permitted in the
             study.

          7. Women of child bearing potential (e.g. not post-menopausal for at least one year or
             surgically sterile) must agree to use adequate birth control for the duration of the
             study and 3 months after last dose of study drug. Women must not be planning to become
             pregnant for the duration of the study and 3 months after last dose of study drug

          8. Men must agree to practice contraception for the duration of the study and 3 months
             after last dose of study drug. Men must not plan to father a child or provide for
             sperm donation for the duration of the study and 3 months after last dose of study
             drug

        Key Exclusion Criteria:

          1. Presence of tracheostomy

          2. Exposure to PB, TUDCA or UDCA within 3 months prior to the Screening Visit or planning
             to use these medications during the course of the study

          3. History of known allergy to PB or bile salts

          4. Abnormal liver function defined as AST and/or ALT &gt; 3 times the upper limit of the
             normal

          5. Renal insufficiency as defined by a serum creatinine &gt; 1.5 times the upper limit of
             normal

          6. Poorly controlled arterial hypertension (SBP&gt;160mmHg or DBP&gt;100mmHg) at the Screening
             Visit

          7. Pregnant women or women currently breastfeeding

          8. History of cholecystectomy

          9. Biliary disease which impedes biliary flow including active cholecystitis, primary
             biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps,
             gangrene of the gallbladder, abscess of the gallbladder.

         10. History of Class III/IV heart failure (per New York Heart Association - NYHA)

         11. Severe pancreatic or intestinal disorders that may alter the enterohepatic circulation
             and absorption of TUDCA including biliary infections, pancreatitis and ileal resection

         12. The presence of unstable psychiatric disease, cognitive impairment, dementia or
             substance abuse that would impair ability of the subject to provide informed consent,
             according to Site Investigator judgment

         13. Clinically significant unstable medical condition (other than ALS) that would pose a
             risk to the subject if they were to participate in the study

         14. Active participation in an ALS clinical trial evaluating a small molecule within 30
             days of the Screening Visit

         15. Exposure at any time to any biologic under investigation for the treatment of subjects
             with ALS (off-label use or investigational) including cell therapies, gene therapies,
             and monoclonal antibodies.

         16. Implantation of Diaphragm Pacing System (DPS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Yeramian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amylyx Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabrina Paganoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forbes Norris MDA/ALS Research Center - California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carol and Frank Morsini Center for Advanced Health Care - University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Neuroscience Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Penn Comprehensive ALS Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALS Center at the Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024041/</url>
    <description>TUDCA in patients with ALS</description>
  </link>
  <link>
    <url>http://www.tandfonline.com/doi/abs/10.1080/17482960802320487?journalCode=iafd19</url>
    <description>Phenylbutyrate in patients with ALS</description>
  </link>
  <reference>
    <citation>Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, La Bella V, Tedeschi G, Albanese A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016 Jan;23(1):45-52. doi: 10.1111/ene.12664. Epub 2015 Feb 9. Erratum in: Eur J Neurol. 2017 Apr;24(4):659.</citation>
    <PMID>25664595</PMID>
  </reference>
  <reference>
    <citation>Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ; Northeast ALS and National VA ALS Research Consortiums. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009 Apr;10(2):99-106. doi: 10.1080/17482960802320487.</citation>
    <PMID>18688762</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>Double-blind</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Sodium Phenylbutyrate</keyword>
  <keyword>Tauroursodeoxycholic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>TDP-43 Proteinopathies</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tauroursodeoxycholic acid</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

